CD8α/β heterodimer: the core co-receptor for cytotoxic T lymphocyte antigen recognition

Author: Senior Product Manager of UA Views：9

This article focuses on the molecular characteristics and immunological functions of the CD8α/β heterodimer, systematically elaborating its transmembrane glycoprotein structure formed by the α chain and β chain, encoded by the CD8A and CD8B genes respectively, assembled through disulfide bonds. It analyzes the changes in the MHC class I molecule binding interface and spatial conformation upon the incorporation of the β chain, as well as the resulting enhancement of antigen-binding affinity, and explores the molecular mechanisms by which CD8αβ cooperates with the TCR to initiate T cell activation and cytotoxic signaling transduction.

Recent Advances
Product Information

Recent Advances

CD8α/β Heterodimer: The Core Co-Receptor for Antigen Recognition by Cytotoxic T Lymphocytes

Brief Introduction: This article focuses on the molecular characteristics and immunological functions of the CD8α/β heterodimer, systematically describing its transmembrane glycoprotein structure formed by the α chain and β chain, which are encoded by the CD8A and CD8B genes respectively, assembled through disulfide bonds. It analyzes the changes in the MHC class I molecule binding interface and spatial conformation caused by the incorporation of the β chain and the resulting enhancement of antigen-binding affinity, and discusses the molecular mechanism by which CD8αβ cooperates with the TCR to initiate T cell activation and cytotoxic signal transduction.

I. Molecular Composition and Gene Encoding of the CD8α/β Heterodimer.

CD8A and CD8B encode the α chain and β chain, respectively, which are linked by disulfide bonds to form the CD8αβ heterodimer, a transmembrane glycoprotein co-receptor expressed on the surface of cytotoxic T lymphocytes. In terms of molecular composition, both CD8α and CD8β belong to the immunoglobulin superfamily, each containing an extracellular immunoglobulin-like domain, a single-pass transmembrane helical region, and an intracellular tail region. The two chains are covalently connected through an interchain disulfide bond to form a stable heterodimeric complex. This receptor structure, assembled from two different gene products, stands in sharp contrast to the CD8αα homodimer and also confers unique ligand recognition properties upon CD8αβ. The CD8α/β heterodimer is mainly expressed on the surface of cytotoxic T lymphocytes and serves as the core molecular basis for recognizing and eliminating target cells in adaptive immunity.

II. Structural Features and Affinity Advantages of the CD8α/β Heterodimer.

Structurally, the CD8α/β heterodimer contains an immunoglobulin-like V-type extracellular domain. The incorporation of the β chain alters the binding interface and spatial conformation with MHC class I molecules, giving it higher antigen-binding affinity than the CD8αα homodimer. This structural difference has important functional significance——through the participation of the β chain, the CD8αβ heterodimer optimizes the binding geometry with the α3 domain of MHC class I molecules, making the interaction between the co-receptor and the TCR-peptide-MHC complex more stable and efficient. Higher antigen-binding affinity means that CD8αβ can effectively assist TCR recognition at lower peptide-MHC densities, thereby enhancing the sensitivity of cytotoxic T lymphocytes to target cells with low antigen density. This structure-function relationship explains why CD8αβ, rather than CD8αα, is the major co-receptor form on mature cytotoxic T lymphocytes.

III. Signal Transduction Function of the CD8α/β Heterodimer.

Functionally, CD8αβ cooperates with the T cell receptor to recognize MHC class I peptide complexes presented by target cells and initiates T cell activation and cytotoxic signal transduction through intracellular Lck kinase, serving as a core molecule of adaptive immunity. Specifically, the intracellular tail region of the CD8α chain binds to Lck kinase. When CD8αβ binds to MHC class I molecules, Lck is recruited near the TCR signaling complex, phosphorylates the ITAM motifs of the CD3 complex and downstream signaling molecules such as ZAP-70, and initiates the cascade of T cell activation. Although the intracellular tail region of the CD8β chain is relatively short, the participation of its extracellular domain is crucial for maintaining effective binding between the co-receptor and MHC class I molecules. This functional division in which “the α chain is responsible for signaling and the β chain optimizes binding” makes the CD8αβ heterodimer a sophisticated molecular device connecting antigen recognition with intracellular signal initiation.

IV. Clinical Relevance of the CD8α/β Heterodimer.

Clinically, the expression level of CD8αβ is closely associated with HIV disease progression and the differentiation of CD8-positive T cell subsets. In HIV infection, changes in the CD8αβ expression pattern of CD8-positive T cells reflect the functional status of T cells and the stage of disease progression. Reduced heterodimer expression can be seen in immunodeficiency diseases such as Wiskott-Aldrich syndrome, suggesting that normal expression of CD8αβ plays an indispensable role in maintaining cytotoxic T lymphocyte function. In addition, as a key marker of tumor-infiltrating lymphocytes and autoimmune diseases, CD8αβ has become an important research target for evaluating immunotherapy efficacy and targeted intervention. In tumor immunotherapy, the density and functional status of CD8αβ-positive tumor-infiltrating lymphocytes are important indicators for assessing the efficacy of immune checkpoint inhibitors; in autoimmune diseases, abnormal activation of CD8αβ-positive T cells participates in the pathological process of tissue damage.

V. Conclusion.

In basic research and immunotherapy development related to the CD8α/β heterodimer, high-quality recombinant CD8αβ protein is a core tool for dissecting its binding mechanism with MHC class I molecules and evaluating targeted intervention strategies. Biotinylated CD8αβ protein can be used with streptavidin-conjugated detection systems for highly sensitive receptor-ligand binding analysis and quantitative detection of cell surface CD8αβ expression. This product adopts a dual-tag design with His tag and Avi tag, facilitating purification by immobilized metal affinity chromatography and site-specific biotinylation. To meet the needs of CD8αβ functional research and immunotherapy strategy exploration, Univ provides Biotinylated CD8 alpha&beta Heterodimer, His, Avi Tag&Tag Free Protein, Human. This product is suitable for applications such as binding activity analysis of CD8αβ with MHC class I molecules, in vitro screening and evaluation of CD8αβ-targeting antibodies, research on CD8αβ-mediated T cell activation signaling pathways, and studies related to tumor-infiltrating lymphocytes and autoimmune diseases.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next